Global pharmaceutical companies, which can be said to be the mainstay of the supply of new drugs. The KRPIA, which represents these companies, is also raising expectations in 2022.

Multinational pharmaceutical companies' attention is more focused on the "appropriate value of new drugs" than ever before. With the advent of the so-called "high-priced drug era," it is becoming increasingly difficult to find a point of contact between the government and the pharmaceutical industry. There are still many discussions and suggestions regarding the drug price system, such as expanding the scope of application of the PE system, introducing pre-registration & post-evaluation, and adding drugs subject to negotiation a